RAFARMA PHARMA (WY) - RAFA STOCK NEWS

Rafarma Pharmaceuticals (OTC: RAFA) announces its participation in a scientific conference focused on radioembolization using Yttrium 90 microspheres for cancer treatment at Severance Hospital in Seoul, South Korea. The nanostructured microspheres are primarily aimed at liver cancer but can also treat other solid tumors. Rafarma is in the process of registering these microspheres in South Korea, the only Asian country using this technology for liver cancer patients under health insurance. Key benefits include minimally invasive procedures, targeted tumor destruction, and improved patient outcomes. Statistics show an increase in average survival from 13 to 27 months and an 89% positive treatment response rate among patients.

Rafarma Pharmaceuticals (OTC: RAFA) announced a preliminary agreement with Woods Medical Care to establish a joint venture in Busan Technology Park, South Korea. This venture aims to produce radiopharmaceuticals and nuclear medicine treatments, including Yttrium-90-based products and lithium-capture therapy units. The initiative will serve East Asian markets, focusing on cancer treatments such as brachytherapy for prostate and liver cancers. The anticipated revenue is $50 million over five years, with potential profits of $20 million within four years. The project requires an estimated $30 million investment.

Rafarma Pharmaceuticals (RAFA) has entered into a preliminary agreement with Kelun Lifesciences (Pvt) Ltd, a pharmaceutical company in Sri Lanka, and the Alberto Masferrer University of El Salvador for joint research, pharmacological development, and implementation of medicines and medical technologies. The agreement includes the creation of production centers for the synthesis of drugs, radiopharmaceuticals, and medical devices, as well as investment and promotion in international markets.

Rafarma Pharmaceuticals (OTC: RAFA) completes restructuring, accounting and balance sheet procedures to comply with GAAP auditing standards. Due to geopolitical changes, assets review for Kraspharma and Bebig is pending. The company is acquiring assets and projects in Kazakhstan, Israel, El Salvador, Sri Lanka, and Hong Kong. Recapitalization through preferred shares, aiming to expand products and manufacturing capabilities globally. Strategic focus on medical research, development, and new product launches. Targeting to become a $2 billion global innovative company by 2025, with a development strategy until 2028 including nuclear medicine, biotechnology, SMART packaging, and research and development.

Rafarma Pharmaceuticals (OTC: RAFA) has expanded its operations in Uzbekistan by planning to build a new pharmaceutical plant in the Tashkent Pharma Park. This facility, adhering to Industry 4.0 standards, aims to produce sterile drugs and fractionated blood plasma elements. The project, expected to generate tens of millions in revenue within 4-5 years, is part of a larger initiative to advance Uzbekistan's pharmaceutical industry. The government is currently preparing regulatory changes to support these developments.

Rafarma Pharmaceuticals (OTC: RAFA) announced its subsidiary, Slavich Noya Technology, is expanding production capabilities by negotiating the acquisition of two advanced machines from BOBST for approximately 1.6 million euros. The Expertfold 80a2 folder-gluer will enhance box production speed up to 450 meters per minute, ideal for pharmaceuticals and cosmetics due to its quality inspection system. The automatic die cutter, NOVACUT 106 E 3.0, features the new BOBST Human Machine Interface and aims to solve product challenges, significantly expanding the company's operational capabilities.

Rafarma Pharmaceuticals (OTC: RAFA) is negotiating with the Joint Institute for Nuclear Research (JINR) to develop projects in nuclear medicine technologies, radiopharmaceuticals, and radiotherapy. The company has existing products such as Yttrium-90 microspheres and iodine-125 micro sources. Additionally, Rafarma is working on a muon radiography project utilizing artificial intelligence for studying large structures, which could aid in geological exploration and early detection of emergencies. Collaborating with JINR will leverage their advanced scientific facilities.

Rafarma Pharmaceuticals (RAFA) has partnered with Czech engineering firm Block to construct a scientific and pharmaceutical complex in Uzbekistan's Tashkent Pharma Park. This project includes a facility aimed at producing over 1 million liters of blood plasma annually, requiring an investment exceeding $50 million. The initiative is set to bolster Uzbekistan's position in the global pharmaceutical landscape, establishing it among the top 10 countries for blood component fractionation. The first phase of construction aims to begin in summer 2022, focusing on cancer drug production.

Rafarma Pharmaceuticals (OTC: RAFA) announced that PJSC Kraspharma ranked among the top five pharmaceutical companies in Russia for 2020, showcasing a remarkable net profit increase of 220.9% from $5,563,056 in 2019 to $17,853,905 in 2020. This growth was featured in the respected publication 'Remedium'. Additionally, Kraspharma achieved a position in the top 30 pharmaceutical companies by gross profit and became a leading manufacturer of antibacterial agents, increasing sales volume of antibiotics by more than 40% during the first three quarters of 2020.